The British “Financial Times” reported that the US pharmaceutical company Moderna refused to transfer the core intellectual property rights of the new crown vaccine at China’s request, and the negotiations on selling its new crown vaccine in China broke down.
According to the report, the Chinese side asked Moderna to provide the mRNA vaccine form as a prerequisite for sales in China, but Moderna refused, citing commercial and safety considerations, describing the company as abandoning its earlier efforts to enter the Chinese market. The sources said Moderna was worried that if a Chinese partner had problems manufacturing a vaccine, it could affect the company’s reputation.
Modena replied to the Financial Times that there had been no discussion with China on supplying the new crown vaccine, but that he was open to supplying the vaccine to any country. (BC)
#modena#mRNA #chinasales
